天臣医疗(688013) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 reached RMB 272,367,248.39, an increase of 7.38% compared to RMB 253,645,801.13 in the previous year[4] - Operating profit for the period was RMB 55,385,594.52, reflecting a year-on-year growth of 19.28% from RMB 46,434,314.23[4] - Net profit attributable to shareholders of the parent company was RMB 52,114,430.36, up 10.15% from RMB 47,311,219.20 in the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 46,757,253.53, representing a significant increase of 24.51% year-on-year[4] - Basic earnings per share increased to RMB 0.65, an 8.33% rise from RMB 0.60 in the previous year[4] Assets and Equity - Total assets at the end of the reporting period amounted to RMB 637,240,337.63, a 1.70% increase from RMB 626,608,586.15 at the beginning of the period[4] - Shareholders' equity attributable to the parent company rose to RMB 581,648,061.90, marking a 1.77% increase from RMB 571,524,539.79[4] Stock Incentive Plan - The company implemented a stock incentive plan, recognizing share-based payment expenses of RMB 1,192.98 million, impacting net profit by RMB 1,014.02 million after tax considerations[7] Marketing Strategy - The company actively adjusted its marketing strategy and increased efforts in overseas market expansion to enhance competitiveness amid external economic challenges[7] Financial Reporting - The financial data presented is preliminary and unaudited, with final figures to be disclosed in the 2024 annual report[8]